Clinical Trial Update: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update comparing gilteritinib versus midostaurin in combination with induction, consolidation, and maintenance in adults with newly diagn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts-2

Drugs mentioned

• Gilteritinib (gilteritinib)
• Midostaurin (midostaurin)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 3 | Status: ACTIVE_NOT_RECRUITING